If this file opens in Compatibility Mode using Microsoft Word, convert to the latest document format to avoid potential formatting issues.	

OP/IP RSH PRO00042634 PINGALI 90014496LYM1001 ARM 1	

Types:      Research Oncology Treatment
Synonyms:  SCREENING

Cycle 1	Repeat 1 time	Cycle length: 8 days	Apheresis	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 68	Interval: --	Occurrences: --	Comments:	Pretreatment criteria check
		  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	ECOG performance
		  	DAILY WEIGHTS	Interval: --	Occurrences: --		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Vital signs, including oxygen saturation.
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 115	Interval: --	Occurrences: --	Comments:	Infectious disease testing for apheresis product (per local regulations)
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
			Nursing Orders
  	ONC NURSING COMMUNICATION 8	Interval: --	Occurrences: --	Comments:	If the patient has a CrCl of 30-70 mL/min, contact provider to discuss dose reductions per approved FDA labeling.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	BILIRUBIN DIRECT	Interval: --	Occurrences: --		  	URIC ACID LEVEL	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	MAGNESIUM LEVEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: --	Occurrences: --		  	FERRITIN LEVEL	Interval: --	Occurrences: --			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Deep immune profiling (whole blood for PBMC)

AP, PI-FU days 11, 15, 90; and PT-FU Pre-PD at 6-, 12-, and 24-months post-infusion
				Lymphodepletion Day - 5	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Provider Communication
  	ONC PROVIDER COMMUNICATION 64	Interval: Once	Occurrences: --	Comments:	Verify Hep B panel status prior to cycle. Date *** of panel. Result positive/negative/pending/unknown:22867

The required components for the hepatitis B panel includes: Hepatitis B surface antigen (HBsAg), total hepatitis B core antibody (anti-HBc), and hepatitis B antibody (anti-HBs).
			Nursing Orders
  	ONC NURSING COMMUNICATION 68	Interval: Once	Occurrences: --	Comments:	Pretreatment criteria check
		  	ONC NURSING COMMUNICATION 37	Interval: Once	Occurrences: --	Comments:	ECOG performance
		  	DAILY WEIGHTS	Interval: Daily	Occurrences: --		  	VITAL SIGNS - T/P/R/BP	Interval: Per unit protocol	Occurrences: --	Comments:	Vital signs, including oxygen saturation.
		  	ONC NURSING COMMUNICATION 10	Interval: Until discontinued	Occurrences: --	Comments:	Temperature. Participants should be advised to monitor their temperature at least once daily for a minimum of 7 days after infusion and report temperature Greater than or Equal to 38 Degree Celsius (Greater than or Equal to 100.4 degree Fahrenheit) immediately to the investigator
		  	ONC NURSING COMMUNICATION 36	Interval: Until discontinued	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: Until discontinued	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: Until discontinued	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
			Nursing Orders
  	ONC NURSING COMMUNICATION 2	Interval: Until discontinued	Occurrences: --	Comments:	If the patient has a CrCl of 30-70 mL/min, contact provider to discuss dose reductions per approved FDA labeling.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: Once	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: Once	Occurrences: --		  	BILIRUBIN DIRECT	Interval: Once	Occurrences: --		  	URIC ACID LEVEL	Interval: Once	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: Once	Occurrences: --		  	MAGNESIUM LEVEL	Interval: Once	Occurrences: --		  	LDH	Interval: Once	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: Once	Occurrences: --		  	FERRITIN LEVEL	Interval: Once	Occurrences: --			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --		  	HCG QUALITATIVE, URINE SCREEN	Interval: Once	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: Once	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: Once	Occurrences: --			Labs
  	IMMUNOGLOBULIN G	Interval: Once	Occurrences: --			Imaging
  	PET CT WHOLE BODY	Interval: 1 time imaging	Occurrences: --			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --		☑	CTA NECK W WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	MRA NECK WO CONTRAST	Interval: 1 time imaging	Occurrences: --			Imaging
  	ECG 12-LEAD	Interval: STAT	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Buccal Swab
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Biomarkers (serum)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly (if previous sample is positive for RCL)
			Line Care
  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Hydration
  	sodium chloride 0.9 % infusion	Dose: 150 mL/hr	Route: intravenous	once over 6 Hours for 1 dose				Instructions:	Start 1 hour prior to chemotherapy.			Pre-Medications
  	palonosetron (ALOXI) injection 0.25 mg	Dose: 0.25 mg	Route: intravenous	once for 1 dose	Start: S				  	fosaprepitant (EMEND) IVPB 150 mg	Dose: 150 mg	Route: intravenous	once over 30 Minutes for 1 dose					  	LORAZepam (ATIVAN) tablet 0.5 mg	Dose: 0.5 mg	Route: oral	once for 1 dose			Offset: 30 Minutes	Instructions:	Administer 30 minutes before chemotherapy
			Chemotherapy
  	MONITOR MINOR INFUSION REACTION	Interval: Until discontinued	Occurrences: --	Comments:	For CrCl 30-70 mg/m2, adjust fludarabine dose to 24 mg/m2
			Chemotherapy
  	INV-CYCLOPHOSPHAMIDE (90014496LYM1001/PRO00042634/PINGALI) 300 mg/m2 in sodium chloride 0.9% 250 mL chemo IVPB	Dose: 300 mg/m2	Route: intravenous	once over 2 Hours for 1 dose			Offset: 90 Minutes	Instructions:	Infuse IV over 2 hours. Stable 24 hr at room temperature or 6 days refrigerated.	Ingredients:	Name	Type	Dose	Selected	Adds Vol.	INV-CYCLOPHOSPHAMIDE 500 MG IV POWDER FOR SOLN (90014496LYM1001/PRO00042634/PINGALI)	Medications	300 mg/m2	Main Ingredient	Yes	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	QS Base	250 mL	Yes	Yes			  	INV-FLUDARABINE (90014496LYM1001/PRO00042634/PINGALI) 30 mg/m2 in sodium chloride 0.9% 100 mL chemo IVPB	Dose: 30 mg/m2	Route: intravenous	once over 30 Minutes for 1 dose			Offset: 210 Minutes	Instructions:	Infuse IV over 30 minutes. Stable 8 hours at room temperature.	Ingredients:	Name	Type	Dose	Selected	Adds Vol.	INV-FLUDARABINE 50 MG INTRAVENOUS SOLN (90014496LYM1001/PRO00042634/PINGALI)	Medications	30 mg/m2	Main Ingredient	Yes	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	QS Base	100 mL	Yes	Yes				Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled				Lymphodepletion Day - 4	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 68	Interval: Once	Occurrences: --	Comments:	Pretreatment criteria check
		  	ONC NURSING COMMUNICATION 37	Interval: Once	Occurrences: --	Comments:	ECOG performance
		  	DAILY WEIGHTS	Interval: Daily	Occurrences: --		  	VITAL SIGNS - T/P/R/BP	Interval: Per unit protocol	Occurrences: --	Comments:	Vital signs, including oxygen saturation.
		  	ONC NURSING COMMUNICATION 10	Interval: Until discontinued	Occurrences: --	Comments:	Temperature. Participants should be advised to monitor their temperature at least once daily for a minimum of 7 days after infusion and report temperature Greater than or Equal to 38 Degree Celsius (Greater than or Equal to 100.4 degree Fahrenheit) immediately to the investigator
		  	ONC NURSING COMMUNICATION 36	Interval: Until discontinued	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: Until discontinued	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: Until discontinued	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
			Nursing Orders
  	ONC NURSING COMMUNICATION 2	Interval: Until discontinued	Occurrences: --	Comments:	If the patient has a CrCl of 30-70 mL/min, contact provider to discuss dose reductions per approved FDA labeling.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: Once	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: Once	Occurrences: --		  	BILIRUBIN DIRECT	Interval: Once	Occurrences: --		  	URIC ACID LEVEL	Interval: Once	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: Once	Occurrences: --		  	MAGNESIUM LEVEL	Interval: Once	Occurrences: --		  	LDH	Interval: Once	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: Once	Occurrences: --		  	FERRITIN LEVEL	Interval: Once	Occurrences: --			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --		  	HCG QUALITATIVE, URINE SCREEN	Interval: Once	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: Once	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: Once	Occurrences: --			Labs
  	IMMUNOGLOBULIN G	Interval: Once	Occurrences: --			Imaging
  	PET CT WHOLE BODY	Interval: 1 time imaging	Occurrences: --			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --		☑	CTA NECK W WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	MRA NECK WO CONTRAST	Interval: 1 time imaging	Occurrences: --			Imaging
  	ECG 12-LEAD	Interval: STAT	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Buccal Swab
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Biomarkers (serum)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly (if previous sample is positive for RCL)
			Line Care
  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Hydration
  	sodium chloride 0.9 % infusion	Dose: 150 mL/hr	Route: intravenous	once over 6 Hours for 1 dose				Instructions:	Start 1 hour prior to chemotherapy.			Pre-Medications
  	LORAZepam (ATIVAN) tablet 0.5 mg	Dose: 0.5 mg	Route: oral	once for 1 dose			Offset: 30 Minutes	Instructions:	Administer 30 minutes before chemotherapy.			Chemotherapy
  	MONITOR MINOR INFUSION REACTION	Interval: Until discontinued	Occurrences: --	Comments:	For CrCl 30-70 mg/m2, adjust fludarabine dose to 24 mg/m2
			Chemotherapy
  	INV-CYCLOPHOSPHAMIDE (90014496LYM1001/PRO00042634/PINGALI) 300 mg/m2 in sodium chloride 0.9% 250 mL chemo IVPB	Dose: 300 mg/m2	Route: intravenous	once over 2 Hours for 1 dose			Offset: 90 Minutes	Instructions:	Infuse IV over 2 hours. Stable 24 hr at room temperature or 6 days refrigerated.	Ingredients:	Name	Type	Dose	Selected	Adds Vol.	INV-CYCLOPHOSPHAMIDE 500 MG IV POWDER FOR SOLN (90014496LYM1001/PRO00042634/PINGALI)	Medications	300 mg/m2	Main Ingredient	Yes	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	QS Base	250 mL	Yes	Yes			  	INV-FLUDARABINE (90014496LYM1001/PRO00042634/PINGALI) 30 mg/m2 in sodium chloride 0.9% 100 mL chemo IVPB	Dose: 30 mg/m2	Route: intravenous	once over 30 Minutes for 1 dose			Offset: 210 Minutes	Instructions:	Infuse IV over 30 minutes. Stable 8 hours at room temperature.	Ingredients:	Name	Type	Dose	Selected	Adds Vol.	INV-FLUDARABINE 50 MG INTRAVENOUS SOLN (90014496LYM1001/PRO00042634/PINGALI)	Medications	30 mg/m2	Main Ingredient	Yes	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	QS Base	100 mL	Yes	Yes				Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled				Lymphodepletion Day -3	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 68	Interval: Once	Occurrences: --	Comments:	Pretreatment criteria check
		  	ONC NURSING COMMUNICATION 37	Interval: Once	Occurrences: --	Comments:	ECOG performance
		  	DAILY WEIGHTS	Interval: Daily	Occurrences: --		  	VITAL SIGNS - T/P/R/BP	Interval: Per unit protocol	Occurrences: --	Comments:	Vital signs, including oxygen saturation.
		  	ONC NURSING COMMUNICATION 10	Interval: Until discontinued	Occurrences: --	Comments:	Temperature. Participants should be advised to monitor their temperature at least once daily for a minimum of 7 days after infusion and report temperature Greater than or Equal to 38 Degree Celsius (Greater than or Equal to 100.4 degree Fahrenheit) immediately to the investigator
		  	ONC NURSING COMMUNICATION 36	Interval: Until discontinued	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: Until discontinued	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: Until discontinued	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
			Nursing Orders
  	ONC NURSING COMMUNICATION 2	Interval: Until discontinued	Occurrences: --	Comments:	If the patient has a CrCl of 30-70 mL/min, contact provider to discuss dose reductions per approved FDA labeling.
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: Once	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: Once	Occurrences: --		  	BILIRUBIN DIRECT	Interval: Once	Occurrences: --		  	URIC ACID LEVEL	Interval: Once	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: Once	Occurrences: --		  	MAGNESIUM LEVEL	Interval: Once	Occurrences: --		  	LDH	Interval: Once	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: Once	Occurrences: --		  	FERRITIN LEVEL	Interval: Once	Occurrences: --			Labs
  	HCG QUALITATIVE, URINE SCREEN	Interval: --	Occurrences: --		  	HCG QUALITATIVE, URINE SCREEN	Interval: Once	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: Once	Occurrences: --		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: Once	Occurrences: --			Labs
  	IMMUNOGLOBULIN G	Interval: Once	Occurrences: --			Imaging
  	PET CT WHOLE BODY	Interval: 1 time imaging	Occurrences: --			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: 1 time imaging	Occurrences: --		☑	CTA NECK W WO CONTRAST	Interval: 1 time imaging	Occurrences: --		☐	MRA NECK WO CONTRAST	Interval: 1 time imaging	Occurrences: --			Imaging
  	ECG 12-LEAD	Interval: STAT	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Buccal Swab
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Biomarkers (serum)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly (if previous sample is positive for RCL)
			Line Care
  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Hydration
  	sodium chloride 0.9 % infusion	Dose: 150 mL/hr	Route: intravenous	once over 6 Hours for 1 dose				Instructions:	Start 1 hour prior to chemotherapy.			Pre-Medications
  	LORAZepam (ATIVAN) tablet 0.5 mg	Dose: 0.5 mg	Route: oral	once for 1 dose			Offset: 30 Minutes	Instructions:	Administer 30 minutes before chemotherapy.			Pre-Medications
  	palonosetron (ALOXI) injection 0.25 mg	Dose: 0.25 mg	Route: intravenous	once for 1 dose	Start: S					Chemotherapy
  	MONITOR MINOR INFUSION REACTION	Interval: Until discontinued	Occurrences: --	Comments:	For CrCl 30-70 mg/m2, adjust fludarabine dose to 24 mg/m2
			Chemotherapy
  	INV-CYCLOPHOSPHAMIDE (90014496LYM1001/PRO00042634/PINGALI) 300 mg/m2 in sodium chloride 0.9% 250 mL chemo IVPB	Dose: 300 mg/m2	Route: intravenous	once over 2 Hours for 1 dose			Offset: 90 Minutes	Instructions:	Infuse IV over 2 hours. Stable 24 hr at room temperature or 6 days refrigerated.	Ingredients:	Name	Type	Dose	Selected	Adds Vol.	INV-CYCLOPHOSPHAMIDE 500 MG IV POWDER FOR SOLN (90014496LYM1001/PRO00042634/PINGALI)	Medications	300 mg/m2	Main Ingredient	Yes	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	QS Base	250 mL	Yes	Yes			  	INV-FLUDARABINE (90014496LYM1001/PRO00042634/PINGALI) 30 mg/m2 in sodium chloride 0.9% 100 mL chemo IVPB	Dose: 30 mg/m2	Route: intravenous	once over 30 Minutes for 1 dose			Offset: 210 Minutes	Instructions:	Infuse IV over 30 minutes. Stable 8 hours at room temperature.	Ingredients:	Name	Type	Dose	Selected	Adds Vol.	INV-FLUDARABINE 50 MG INTRAVENOUS SOLN (90014496LYM1001/PRO00042634/PINGALI)	Medications	30 mg/m2	Main Ingredient	Yes	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	QS Base	100 mL	Yes	Yes				Discharge Nursing Orders
☑	sodium chloride 0.9 % flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☑	HEParin, porcine (PF) injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.				Prizlo-Cel Infusion (INF) - Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 68	Interval: Until discontinued	Occurrences: --	Comments:	Pretreatment criteria check
		  	ONC NURSING COMMUNICATION 37	Interval: Until discontinued	Occurrences: --	Comments:	ECOG performance
		  	ONC NURSING COMMUNICATION 69	Interval: Until discontinued	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
		  	DAILY WEIGHTS	Interval: Daily	Occurrences: --		  	VITAL SIGNS - T/P/R/BP	Interval: Per unit protocol	Occurrences: --	Comments:	Vital signs, including oxygen saturation. INF: 15 ±5 min prior to JNJ- 90014496 infusion and at the end of infusion
		  	ONC NURSING COMMUNICATION 10	Interval: Until discontinued	Occurrences: --	Comments:	Temperature. Participants should be advised to monitor their temperature at least once daily for a minimum of 7 days after infusion and report temperature Greater than or Equal to 38 Degree Celsius (Greater than or Equal to 100.4 degree Fahrenheit) immediately to the investigator
		  	ONC NURSING COMMUNICATION 52	Interval: Until discontinued	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: Until discontinued	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: Until discontinued	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: Until discontinued	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: Until discontinued	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: Until discontinued	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: Until discontinued	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: Once	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: Once	Occurrences: --		  	BILIRUBIN DIRECT	Interval: Once	Occurrences: --		  	URIC ACID LEVEL	Interval: Once	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: Once	Occurrences: --		  	MAGNESIUM LEVEL	Interval: Once	Occurrences: --		  	LDH	Interval: Once	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: Once	Occurrences: --		  	FERRITIN LEVEL	Interval: Once	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: Once	Occurrences: --	Comments:	AS CLINICALLY INDICATED
		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: Once	Occurrences: --	Comments:	AS CLINICALLY INDICATED
			Imaging
  	ECG 12-LEAD	Interval: STAT	Occurrences: --			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Nursing Orders
  	ONC NURSING COMMUNICATION 2	Interval: Once	Occurrences: --	Comments:	Prior to infusion, verify with pharmacy that 2 doses of tocilizumab are available and set aside for this patient.
			Line Care
  	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN	Start: S					Line Care
  	sodium chloride 0.9 % infusion 250 mL	Dose: 250 mL	Route: intravenous	once @ 30 mL/hr for 1 dose	Start: S			Instructions:	To keep vein open.			Pre-Medications
  	acetaminophen (TYLENOL) tablet 650 mg	Dose: 650 mg	Route: oral	once for 1 dose	Start: S			Instructions:	Premed for CAR-T Infusion		  	diphenhydrAMINE (BENADRYL) injection 12.5 mg	Dose: 12.5 mg	Route: intravenous	once for 1 dose	Start: S			Instructions:	Premed for CAR-T Infusion			Chemotherapy
  	INV-Prizlo-cell CAR-T cell infusion (90014496LYM1001/Pro00042634/Pingali) 75 MILLION CAR-positive viable T-cells	Dose: 75 MILLION CAR-positive viable T-cells	Route: intravenous	once for 1 dose			Offset: 30 Minutes	Instructions:	Administer IV by gravity via peripheral or central line. Gently agitate bag during infusion to prevent cell clumps. Flush line with NS at the same administration rate. Expires 90 minutes after thaw.			CAR-T Infusion Additional Orders
  	ONC NURSING COMMUNICATION 74	Interval: Once	Occurrences: --	Comments:	Transplant Orders: 
-Oxygen at bedside during CAR-T infusion and until discharged.
-Anaphylaxis precautions at bedside during CAR-T infusion and until discharged.
		  	ONC NURSING COMMUNICATION 75	Interval: Once	Occurrences: --	Comments:	- Obtain baseline vital signs (T, P, R, BP, Oxygen saturation +/- breath sounds) 
- Vital signs every 15 minutes during infusion (T, P, R, BP) 
- Vital signs (T, P, R, BP, +/- breath sounds) at completion of infusion, then at 30 minutes post & 60 minutes post infusion
		  	PULSE OXIMETRY CONTINUOUS	Interval: Continuous	Occurrences: --	Comments:	Continuous pulse oximetry monitoring during infusion and for 30 minutes post infusion
		  	ONC NURSING COMMUNICATION 80	Interval: Once	Occurrences: --	Comments:	RECORD START & STOP TIMES on component infusion form AND in EPIC
		  	meperidine (DEMEROL) injection (RESTRICTED) 12.5 mg	Dose: 12.5 mg	Route: intravenous	every 15 min PRN for 3 doses					  	epINEPHrine (ADRENALIN) 1 mg/1 mL injection 0.3 mg	Dose: 0.3 mg	Route: subcutaneous	PRN	Start: S				  	diphenhydrAMINE (BENADRYL) injection 25 mg	Dose: 25 mg	Route: intravenous	PRN	Start: S					Discharge Nursing Orders
☑	sodium chloride 0.9% flush 20 mL	Dose: 20 mL	Route: intravenous	PRN					☐	HEParin, porcine injection 500 Units	Dose: 500 Units	Route: intra-catheter	once PRN	Start: S			Instructions:	Concentration: 100 units/mL. Heparin flush for Implanted Vascular Access Device maintenance.			Discharge Nursing Orders
  	alteplase (CATHFLO) for NON Quinton and NON Hemodialysis Catheters 2 mg	Dose: 2 mg	Route: intra-catheter	once PRN	Start: S			Instructions:	HOLD and notify provider if Platelets LESS than 50.  Instill dose into occluded catheter. Do not force solution into
catheter. After a 30-minute dwell time, assess catheter function by attempting
to aspirate blood. If catheter is functional, aspirate 4 to 5 mL of blood in
patients greater than or equal to 10 kg to remove Cathflo Activase and
residual clots. Gently irrigate the catheter with NS. If catheter remains
nonfunctional, let Cathflo Activase dwell for another 90 minutes (total dwell
time: 120 minutes) and reassess function. If catheter function is not restored,
a second dose may be instilled					
Post-Infusion Follow-up: PI-FU	Repeat 1 time	Cycle length: 90 days	Day 5	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Biomarkers (serum)
				Day 8	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 68	Interval: --	Occurrences: --	Comments:	Temperature: Participants should be advised to monitor their temperature at least once daily for a minimum of 7 days after infusion and report temperature GREATER THAN or EQUAL TO 38 degrees celsius (GREATER THAN or EQUAL TO 100.4 degrees fahrenheit) immediately to the investigator
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Vital signs, including oxygen saturation.
		  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - As CLINICALLY INDICATED
		  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	BILIRUBIN DIRECT	Interval: --	Occurrences: --		  	URIC ACID LEVEL	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	MAGNESIUM LEVEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: --	Occurrences: --		  	FERRITIN LEVEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --	Comments:	AS CLINICALLY INDICATED
		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --	Comments:	AS CLINICALLY INDICATED
			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Biomarkers (serum)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
				Day 11	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Deep immune profiling (whole blood for PBMC)

AP, PI-FU days 11, 15, 90; and PT-FU Pre-PD at 6-, 12-, and 24-months post-infusion
				Day 15	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Vital signs, including oxygen saturation. INF: 15 ±5 min prior to JNJ- 90014496 infusion and at the end of infusion
		  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - As CLINICALLY INDICATED
		  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	BILIRUBIN DIRECT	Interval: --	Occurrences: --		  	URIC ACID LEVEL	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	MAGNESIUM LEVEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: --	Occurrences: --		  	FERRITIN LEVEL	Interval: --	Occurrences: --			Labs
  	PROTHROMBIN TIME WITH INR	Interval: --	Occurrences: --	Comments:	AS CLINICALLY INDICATED
		  	PARTIAL THROMBOPLASTIN TIME (PTT)	Interval: --	Occurrences: --	Comments:	AS CLINICALLY INDICATED
			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Biomarkers (serum)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Deep immune profiling (whole blood for PBMC)

AP, PI-FU days 11, 15, 90; and PT-FU Pre-PD at 6-, 12-, and 24-months post-infusion
				Day 22	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Vital signs, including oxygen saturation. INF: 15 ±5 min prior to JNJ- 90014496 infusion and at the end of infusion
		  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - As CLINICALLY INDICATED
		  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	BILIRUBIN DIRECT	Interval: --	Occurrences: --		  	URIC ACID LEVEL	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	MAGNESIUM LEVEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: --	Occurrences: --		  	FERRITIN LEVEL	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Biomarkers (serum)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
				Day 29	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	ECOG performance
		  	VITAL SIGNS - T/P/R/BP	Interval: --	Occurrences: --	Comments:	Vital signs, including oxygen saturation. INF: 15 ±5 min prior to JNJ- 90014496 infusion and at the end of infusion
		  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - As CLINICALLY INDICATED
		  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	BILIRUBIN DIRECT	Interval: --	Occurrences: --		  	URIC ACID LEVEL	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	MAGNESIUM LEVEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: --	Occurrences: --		  	FERRITIN LEVEL	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	ctDNA analysis.

PI-FU days 29, 90; PT-FU at 12- and 24-months post-infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
				Day 60	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	ECOG performance
		  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - As CLINICALLY INDICATED
		  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	BILIRUBIN DIRECT	Interval: --	Occurrences: --		  	URIC ACID LEVEL	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	MAGNESIUM LEVEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: --	Occurrences: --		  	FERRITIN LEVEL	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
				Day 90	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Please refer to Study Protocol for any questions or discrepancies. See Schedule of Events Calendar for sequence of diagnostic tests, examinations, and treatment administration: See Safety Parameters-for Toxicity Management and Dose Modification Guidelines: Protocol Access hyperlink:    90014496LYM1001_Pingali
		  	ONC NURSING COMMUNICATION 5	Interval: Until discontinued	Occurrences: --	Comments:	Nursing Communication: Dose Modifications and Management for study is NOT APPLICABLE Treatment: Refer to Section 6.6 (DOSE MODIFICATION) 
Protocol Access Hyperlink:  [CG1] 90014496LYM1001_Pingali
			Nursing Orders
  	ONC NURSING COMMUNICATION 37	Interval: --	Occurrences: --	Comments:	ECOG performance
		  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - As CLINICALLY INDICATED
		  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Labs
  	CBC WITH PLATELET AND DIFFERENTIAL	Interval: --	Occurrences: --		  	COMPREHENSIVE METABOLIC PANEL	Interval: --	Occurrences: --		  	BILIRUBIN DIRECT	Interval: --	Occurrences: --		  	URIC ACID LEVEL	Interval: --	Occurrences: --		  	PHOSPHORUS LEVEL	Interval: --	Occurrences: --		  	MAGNESIUM LEVEL	Interval: --	Occurrences: --		  	LDH	Interval: --	Occurrences: --		  	C-REACTIVE PROTEIN	Interval: --	Occurrences: --		  	FERRITIN LEVEL	Interval: --	Occurrences: --			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	ctDNA analysis.

PI-FU days 29, 90; PT-FU at 12- and 24-months post-infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Deep immune profiling (whole blood for PBMC)

AP, PI-FU days 11, 15, 90; and PT-FU Pre-PD at 6-, 12-, and 24-months post-infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly yearly (±
60 days) (if previous sample is positive for RCL)
					
Post-Treatment Follow-up until EOS - Pre-PD: Q3 months post infusion	Repeat 1 time	Cycle length: 90 days	Pre-PD - Month 3	Perform every 90 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
				Pre PD  - Month 6	Perform every 90 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Deep immune profiling (whole blood for PBMC)

AP, PI-FU days 11, 15, 90; and PT-FU Pre-PD at 6-, 12-, and 24-months post-infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly yearly (±
60 days) (if previous sample is positive for RCL)
				Pre PD  - Month 9	Perform every 90 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
				Pre PD  - Month 12	Perform every 90 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Deep immune profiling (whole blood for PBMC)

AP, PI-FU days 11, 15, 90; and PT-FU Pre-PD at 6-, 12-, and 24-months post-infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly yearly (±
60 days) (if previous sample is positive for RCL)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	ctDNA analysis.

PI-FU days 29, 90; PT-FU at 12- and 24-months post-infusion
				Pre-PD - Month 18	Perform every 90 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
				Pre PD  - Month 24	Perform every 90 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Labs
  	IMMUNOGLOBULIN G	Interval: --	Occurrences: --			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Imaging
  	PET CT WHOLE BODY	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. FDG-avid lymphoma. FDG-avid lymphoma
			Imaging
☐	CT CHEST W CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST WO CONTRAST ABDOMEN WO CONTRAST PELVIS WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CT CHEST W CONTRAST ABDOMEN W WO CONTRAST PELVIS W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	CT CHEST W WO CONTRAST ABDOMEN W CONTRAST PELVIS W CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☑	CTA NECK W WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
		☐	MRA NECK WO CONTRAST	Interval: --	Occurrences: --	Comments:	<=7d prior to 1st LD dose. Non-FDG-avid indolent lymphomas
			Procedures
  	BIOPSY BONE MARROW	Interval: --	Occurrences: --	Comments:	Bone marrow biopsy and/or aspirate.At radiologic CR in participants with baseline bone marrow disease
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Deep immune profiling (whole blood for PBMC)

AP, PI-FU days 11, 15, 90; and PT-FU Pre-PD at 6-, 12-, and 24-months post-infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly yearly (±
60 days) (if previous sample is positive for RCL)
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	ctDNA analysis.

PI-FU days 29, 90; PT-FU at 12- and 24-months post-infusion
					
Progressive disease	Repeat 1 time	Cycle length: 1 day	Day 1	Perform every 1 day x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Tumor biopsy
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: Once	Occurrences: --	Comments:	Immunogenicity/ADA (serum)

Pre INF, PI-FU days 15, 29, 60, 90; PT-FU at 6- and 12-months post-infusion and then yearly [± 60 days] until EOS; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	Peripheral immunophenotyping (whole blood)

AP, LD, INF, PI-FU days 8, 11, 15, 22, 29, 60, 90; and PT-FU Pre-PD at 6, 12, 18, 24 months; at PD
					
Post-Treatment Follow-up until EOS -  Post-PD : Q6 months Post PD	Repeat 1 time	Cycle length: 180 days	Post PD - 6 Month	Perform every 180 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Nursing Orders
  	ONC NURSING COMMUNICATION 6	Interval: --	Occurrences: --	Comments:	Subsequent anti-lymphoma therapies and survival information
			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly yearly (±
60 days) (if previous sample is positive for RCL)
				Post PD - 12 Month	Perform every 180 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Nursing Orders
  	ONC NURSING COMMUNICATION 6	Interval: --	Occurrences: --	Comments:	Subsequent anti-lymphoma therapies and survival information
			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly yearly (±
60 days) (if previous sample is positive for RCL)
				Post PD - 18 Month	Perform every 180 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Nursing Orders
  	ONC NURSING COMMUNICATION 6	Interval: --	Occurrences: --	Comments:	Subsequent anti-lymphoma therapies and survival information
			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
				Post PD - 24 Month	Perform every 180 days x1			Research tolerance: -0/+0 days	Nursing Orders
  	ONC NURSING COMMUNICATION 52	Interval: --	Occurrences: --	Comments:	ICE Score. ICE test must be repeated at any incidence of suspected CAR-T cell-related neurotoxicity (eg, ICANS). Perform at least daily until resolution
		  	ONC NURSING COMMUNICATION 35	Interval: --	Occurrences: --	Comments:	FACT-Lym and PGI-S
		  	ONC NURSING COMMUNICATION 36	Interval: --	Occurrences: --	Comments:	Concomitant medications. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. Only treatments for AEs thereafter
		  	ONC NURSING COMMUNICATION 38	Interval: --	Occurrences: --	Comments:	Adverse events. Continuous from signing ICF until 90 days post-infusion of JNJ-90014496. All SAEs and non-serious AEs related to JNJ-90014496 thereafter
		  	ONC NURSING COMMUNICATION 47	Interval: --	Occurrences: --	Comments:	Second primary malignancies. From signing ICF until EOS
		  	ONC NURSING COMMUNICATION 53	Interval: --	Occurrences: --	Comments:	Delayed AEs. From JNJ-90014496 infusion until EOS
		  	ONC NURSING COMMUNICATION 54	Interval: --	Occurrences: --	Comments:	Medical resource utilization. From JNJ-90014496 infusion until 6 months post-infusion
			Nursing Orders
  	ONC NURSING COMMUNICATION 69	Interval: --	Occurrences: --	Comments:	Physical Exam - Perform as CLINICALLY INDICATED
			Nursing Orders
  	ONC NURSING COMMUNICATION 6	Interval: --	Occurrences: --	Comments:	Subsequent anti-lymphoma therapies and survival information
			Labs
  	HEPATITIS C ANTIBODY	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS C VIRUS (HCV) RNA, DIAGNOSIS	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE AB, QUANTITATIVE	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B SURFACE ANTIGEN	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B CORE ANTIBODY TOTAL	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
		  	HEPATITIS B VIRUS (HBV), QUANTITATIVE, DNA (ABBOTT REALTIME)	Interval: --	Occurrences: --	Comments:	Participants with a history of HBV and/or HCV infection: every 3 months for the first 12 months after JNJ-90014496 infusion
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	JNJ-90014496 CAR transgene copy number (PK) (whole blood).

Pre INF, PI-FU days 5, 8, 11, 15, 22, 29, 60, 90; and PT-FU at 6, 12 months post-infusion and then yearly [± 60 days] until EOS, or 2 consecutive samples with undetectable transgene levels, whichever is earlier; at PD
			Research Labs
  	RESEARCH STUDY SPECIMEN	Interval: --	Occurrences: --	Comments:	RCL testing (whole blood)

LD, PI-FU day 90; PT-FU at 6, 12 months post-infusion and then yearly yearly (±
60 days) (if previous sample is positive for RCL)